Literature DB >> 28233184

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.

Bincy P Abraham1, Tasneem Ahmed2, Tauseef Ali3.   

Abstract

Inflammatory bowel diseases, most commonly categorized as Crohn's disease and ulcerative colitis, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial with different environmental, genetic, immune mediated, and gut microbial factors playing important role. The current goals of therapy are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents, with their indications, mechanisms of action, and side effects are discussed in this chapter. Anti-integrin therapy, a newer therapeutic class, with its potential beneficial role in both Crohn's disease and ulcerative colitis is also mentioned. In the end, therapeutic algorithms for both diseases are reviewed.

Entities:  

Keywords:  Adaptive immunity; Anti integrins; Anti-TNF drugs; Biologics; Corticosteroids; Crohn’s disease; Immunomodulators; Inflammation; Inflammatory bowel disease; Innate immunity; Mesalamine; Ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28233184     DOI: 10.1007/164_2016_122

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  23 in total

Review 1.  Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.

Authors:  Bojana Simovic Markovic; Tatjana Kanjevac; C Randall Harrell; Marina Gazdic; Crissy Fellabaum; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

2.  Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis.

Authors:  Moein Eskandari; Fereshteh Asgharzadeh; Mohammad Mostafa Askarnia-Faal; Hamideh Naimi; Amir Avan; Mitra Ahadi; Hassan Vossoughinia; Masoumeh Gharib; Atena Soleimani; Niloufar Naghibzadeh; Gordon Ferns; Mikhail Ryzhikov; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

3.  Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis.

Authors:  Pedro A Ruiz Castro; Ulrike Kogel; Giuseppe Lo Sasso; Blaine W Phillips; Alain Sewer; Bjorn Titz; Llenalia Garcia; Athanasios Kondylis; Emmanuel Guedj; Dariusz Peric; David Bornand; Remi Dulize; Celine Merg; Maica Corciulo; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  J Inflamm (Lond)       Date:  2020-08-24       Impact factor: 4.981

Review 4.  Nitric oxide in the gastrointestinal tract: opportunities for drug development.

Authors:  John L Wallace
Journal:  Br J Pharmacol       Date:  2018-12-03       Impact factor: 8.739

5.  Artificial Intelligence Algorithm-Based Differential Diagnosis of Crohn's Disease and Ulcerative Colitis by CT Image.

Authors:  Fangyun Jiang; Xiaoping Fu; Kai Kuang; Dan Fan
Journal:  Comput Math Methods Med       Date:  2022-04-04       Impact factor: 2.238

Review 6.  Preoperative Nutritional Conditioning of Crohn's Patients-Systematic Review of Current Evidence and Practice.

Authors:  Fabian Grass; Basile Pache; David Martin; Dieter Hahnloser; Nicolas Demartines; Martin Hübner
Journal:  Nutrients       Date:  2017-06-01       Impact factor: 5.717

7.  N-Methylcytisine Ameliorates Dextran-Sulfate-Sodium-Induced Colitis in Mice by Inhibiting the Inflammatory Response.

Authors:  Yan-Fang Jiao; Min Lu; Yu-Ping Zhao; Ning Liu; Ya-Ting Niu; Yang Niu; Ru Zhou; Jian-Qiang Yu
Journal:  Molecules       Date:  2018-02-25       Impact factor: 4.411

8.  Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression.

Authors:  Amira M Abdelmegid; Fadia K Abdo; Fayza E Ahmed; Asmaa A A Kattaia
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

9.  Systems biology approach highlights mechanistic differences between Crohn's disease and ulcerative colitis.

Authors:  Pedro A Ruiz Castro; Hasmik Yepiskoposyan; Sylvain Gubian; Florian Calvino-Martin; Ulrike Kogel; Kasper Renggli; Manuel C Peitsch; Julia Hoeng; Marja Talikka
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

10.  Experimental colitis reduces microglial cell activation in the mouse brain without affecting microglial cell numbers.

Authors:  Hoda M Sroor; Ahmed M Hassan; Geraldine Zenz; Paulina Valadez-Cosmes; Aitak Farzi; Peter Holzer; Amany El-Sharif; Fatma Al-Zahraa M Gomaa; Julia Kargl; Florian Reichmann
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.